California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
Environmental Group Sues to Block Trump Image on U.S. National Park Passes 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Federal Judge Blocks Trump Administration’s Pause on New Wind-Energy Permits 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
Bolivia’s Ex-President Luis Arce Detained in Embezzlement Probe 
Federal Appeals Court Allows Trump’s National Guard Deployment in Washington, D.C. to Continue 
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Chemours, Dupont De Nemours, and Corteva have announced a $110 million settlement with the U.S. state of Ohio to resolve claims linked to toxic "forever chemicals." This agreement aims to address concerns surrounding per- and polyfluoroalkyl substances (PFAS).
Nasdaq reported that the chemical has been associated with various health risks. The settlement covers costs related to the release of PFAS from the companies' facilities, including the Washington Works site situated along the Ohio-West Virginia border, as per Reuters.
Responsibility Distribution for Settlement Costs
According to the agreement, Chemours, a spin-off of DuPont, will bear 50% of the settlement costs, while DuPont will contribute approximately $39 million. Corteva, on the other hand, is expected to cover the remaining expenses. The resolution brings an end to Ohio's claims concerning the release of PFAS, affording the state an opportunity to address this issue comprehensively.
The resolution of the Ohio settlement emphasizes the importance of addressing the wide-reaching implications of PFAS contamination.
Notably, the settlement between the companies and Ohio has triggered a contingency provision outlined in Delaware's 2021 PFAS settlement with the same entities.
This provision requires an additional payment of $25 million to the state of Delaware and the original $50 million settlement if a similar agreement is reached within eight years with another state, amounting to over $50 million. This provision underlines the accountability held by chemical manufacturers in addressing the concerns associated with PFAS contamination.
Legal Battles Surrounding PFAS
Chemical manufacturers have faced numerous lawsuits in recent years regarding alleged PFAS contamination. In a significant ruling, a U.S. appeals court rejected a lower court's decision that would have allowed approximately 11.8 million Ohio residents to sue 10 PFAS manufacturers as a collective group. The legal landscape demonstrates the complexity surrounding PFAS-related claims and the efforts to hold responsible parties accountable for their actions.
In June, 3M agreed to a $10.3 billion settlement to address hundreds of claims alleging the company had contaminated public drinking water with PFAS. Similarly, Chemours, DuPont, and Corteva reached a separate settlement with U.S. water providers, amounting to $1.19 billion.
These settlements underscore the growing recognition within the industry regarding the need to address PFAS-related concerns and the responsibility manufacturers bear in ensuring the safety of their products and practices.
Photo: DuPont Newsroom
